The "late sodium current" (I<sub>NaL</sub>) is a sustained component of the fast Na<sup>+</sup> current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal I<sub>NaL</sub> enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfunction. For this reason, I<sub>NaL</sub> has become an appealing pharmacological target, with a potentially broad range of therapeutic indications. The recent approval by the FDA of an I<sub>NaL</sub> blocker (ranolazine) for clinical use justifies the increased interest in I<sub>NaL</sub> as a pathogenic mechanism and the rapid evolution of the information concerning it. The review focuses on cardiac aspects of I<sub>NaL</sub> enhancement; it deals with the origin of I<sub>NaL</sub>, with its pathophysiological role and with the consequences of its pharmacological modulation. Both basic aspects and clinical evidence are discussed. © 2008 Elsevier Inc. All rights reserved.

Zaza, A., Belardinelli, L., & Shryock, J. (2008). Pathophysiology and pharmacology of the cardiac "late sodium current". PHARMACOLOGY & THERAPEUTICS, 119(3), 326-339 [10.1016/j.pharmthera.2008.06.001].

Pathophysiology and pharmacology of the cardiac "late sodium current"

ZAZA, ANTONIO;
2008-07-01

Abstract

The "late sodium current" (INaL) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal INaL enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfunction. For this reason, INaL has become an appealing pharmacological target, with a potentially broad range of therapeutic indications. The recent approval by the FDA of an INaL blocker (ranolazine) for clinical use justifies the increased interest in INaL as a pathogenic mechanism and the rapid evolution of the information concerning it. The review focuses on cardiac aspects of INaL enhancement; it deals with the origin of INaL, with its pathophysiological role and with the consequences of its pharmacological modulation. Both basic aspects and clinical evidence are discussed. © 2008 Elsevier Inc. All rights reserved.
Articolo in rivista - Articolo scientifico
Late Na+ current; Long QT syndromes; Cardiac arrhythmias; Myocardial remodeling; Myocardial ischemia; Na+ channel blockers
English
326
339
Zaza, A., Belardinelli, L., & Shryock, J. (2008). Pathophysiology and pharmacology of the cardiac "late sodium current". PHARMACOLOGY & THERAPEUTICS, 119(3), 326-339 [10.1016/j.pharmthera.2008.06.001].
Zaza, A; Belardinelli, L; Shryock, J
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/6767
Citazioni
  • Scopus 153
  • ???jsp.display-item.citation.isi??? 134
Social impact